Nano-X Imaging Ltd.
NNOX Healthcare Medical Devices
Nano-X Imaging Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $13.0 million, up 15.4% from fiscal 2024. In the quarter to June 2026, revenue grew 36.7%, EPS fell 243.5%, free cash flow fell 21.4% and total debt fell 12.0%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow NNOX
Nano-X Imaging Ltd. (NNOX) Altman Z-score
Nano-X Imaging Ltd.'s Altman Z-score for fiscal 2025 is −0.16, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −0.16 | (9.34) |
| FY2024 | 9.18 | 2.41 |
| FY2023 | 6.76 | 3.21 |
| FY2022 | 3.55 | (1.39) |
| FY2021 | 4.94 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.31 | — | 0.37 | |
| Retained earnings / total assets | (2.77) | — | −3.87 | |
| EBIT / total assets | (0.48) | — | −1.59 | |
| Market value of equity / total liabilities | 8.09 | — | 4.85 | |
| Sales / total assets | 0.08 | — | 0.08 | |
| Altman Z-score | Distress zone | −0.16 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −3.70 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| SRTS Sensus Healthcare, Inc. compare | 8.9× |
| XTNT Xtant Medical Holdings, Inc. compare | 0.0× |
| QTI QT Imaging Holdings, Inc. compare | 0.0× |
| NNOX Nano-X Imaging Ltd. | −0.2× |
| SNWV Sanuwave Health Inc. compare | −3.0× |
| ELUT Elutia Inc. compare | −4.1× |
| TELA TELA Bio, Inc. compare | −5.9× |
| CVRX CVRx, Inc. compare | −6.3× |
| RPID Rapid Micro Biosystems, Inc. compare | −8.9× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets